Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Killer cell lectin-like receptor subfamily K member 1 (NKG2D) is a major activating receptor primarily expressed on natural killer (NK) cells and a co-stimulatory receptor on CD8+ T cells and γδ T cells [UniProt, PubMed]. It functions by recognizing a diverse set of stress-induced ligands, including MHC class I polypeptide-related sequence A (MICA), MICB, and UL16-binding proteins (ULBPs), which are upregulated on the surface of cells undergoing malignant transformation, viral infection, or DNA damage [NIH, PubMed]. Upon ligand binding, NKG2D signals through the adaptor protein DAP10 to trigger the release of cytotoxic granules and pro-inflammatory cytokines, facilitating the elimination of stressed or abnormal cells [Wikipedia, PubMed]. In the context of cancer, the NKG2D receptor–ligand axis is a key target for immunotherapy, with strategies including CAR-T/NK cells (e.g., CYAD-01), bispecific engagers, and drugs that upregulate ligand expression to overcome tumor immune escape mechanisms like ligand shedding [PMC, PubMed]. Conversely, in autoimmune diseases, the axis is targeted for inhibition to prevent the destruction of healthy tissues by overactive NK and T cells [Frontiers, PubMed].
Activation of NK cell and T cell cytotoxicity via NKG2D-DAP10 signaling; blockade of the NKG2D receptor to inhibit autoimmune responses; pharmacological upregulation of stress-induced ligands (MICA/B, ULBPs) on target cells; and prevention of ligand shedding to maintain immune recognition.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Killer cell lectin-like receptor subfamily K member 1 (NKG2D) (NKG2D).